JP4733631B2 - 抗ウイルス性を有する置換されたジヒドロキナゾリン類 - Google Patents

抗ウイルス性を有する置換されたジヒドロキナゾリン類 Download PDF

Info

Publication number
JP4733631B2
JP4733631B2 JP2006505178A JP2006505178A JP4733631B2 JP 4733631 B2 JP4733631 B2 JP 4733631B2 JP 2006505178 A JP2006505178 A JP 2006505178A JP 2006505178 A JP2006505178 A JP 2006505178A JP 4733631 B2 JP4733631 B2 JP 4733631B2
Authority
JP
Japan
Prior art keywords
trifluoromethyl
alkyl
methyl
fluorine
represents hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006505178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525249A (ja
Inventor
ブンベルク，トビアス
バウマイスター，ユデイト
ベツ，ウルリヒ
イエシユケ，マリオ
ランペ，トマス
ニコリク，スザンネ
リーフシユレガー，ユルゲン
シヨーヘ−ロープ，ルドルフ
ズスマイアー，フランク
ジマーマン，ホルガー
グロサー，ロルフ
ヘニンガー，ケルステイン
ヒユーレツト，ガイ
ケルデニヒ，イエルク
ラング，デイーター
ネル，ペーター
Original Assignee
アイクリス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4733631(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アイクリス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト filed Critical アイクリス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト
Publication of JP2006525249A publication Critical patent/JP2006525249A/ja
Application granted granted Critical
Publication of JP4733631B2 publication Critical patent/JP4733631B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006505178A 2003-05-02 2004-04-17 抗ウイルス性を有する置換されたジヒドロキナゾリン類 Expired - Lifetime JP4733631B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10319612.9 2003-05-02
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Publications (2)

Publication Number Publication Date
JP2006525249A JP2006525249A (ja) 2006-11-09
JP4733631B2 true JP4733631B2 (ja) 2011-07-27

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505178A Expired - Lifetime JP4733631B2 (ja) 2003-05-02 2004-04-17 抗ウイルス性を有する置換されたジヒドロキナゾリン類

Country Status (38)

Country Link
US (4) US7196086B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1622880B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4733631B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100927063B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100393706C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR044078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE355280T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2004233978B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0410029B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2524069C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2004000930A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5700764A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1106476T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10319612A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1622880T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP056138A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG25273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2284007T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1029I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HN (1) HN2004000146A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUS1800018I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL171513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27794A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05011707A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY144616A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300933I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO333265B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ543317A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20050145A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1622880T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1622880E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2360912C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1622880T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI335912B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA82519C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY28294A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004096778A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200508710B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
ES2730958T3 (es) * 2013-06-19 2019-11-13 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral
US9890128B2 (en) 2013-12-12 2018-02-13 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
US10392353B2 (en) * 2015-11-24 2019-08-27 Merck Sharp & Dohme Corp. Processes for making substituted quinazoline compounds using hydrogen bonding catalysts
WO2018028556A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 抗hcmv病毒化合物
AU2019218150B2 (en) 2018-02-08 2021-05-13 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
JP7417715B2 (ja) 2019-09-26 2024-01-18 ノバルティス アーゲー 抗ウイルスピラゾロピリジノン化合物
AR121437A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético
AR121440A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales
AR121439A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
CA3189271A1 (en) 2020-08-17 2022-02-24 Girij Pal Singh A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
KR20010113820A (ko) 1999-04-19 2001-12-28 시오노 요시히코 옥사디아졸 고리를 갖는 술폰아미드 유도체
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DK1325008T3 (da) * 2000-07-31 2006-02-13 Hoffmann La Roche Piperazinderivater
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2002085869A1 (de) 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamide als antivirale mittel
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
AU2006208084B2 (en) * 2005-01-25 2012-07-26 Prolexys Pharmaceuticals, Inc. Quinoxaline Derivatives as Antitumor Agents
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
BRPI0613604A2 (pt) * 2005-07-21 2011-01-18 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
ES2730958T3 (es) * 2013-06-19 2019-11-13 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral

Also Published As

Publication number Publication date
KR20060009883A (ko) 2006-02-01
CN100393706C (zh) 2008-06-11
UY28294A1 (es) 2004-11-30
USRE49698E1 (en) 2023-10-17
BRPI0410029A (pt) 2006-04-25
CO5700764A2 (es) 2006-11-30
EP1622880A1 (de) 2006-02-08
HN2004000146A (es) 2008-06-24
US20050065160A1 (en) 2005-03-24
MXPA05011707A (es) 2006-02-13
SI1622880T1 (sl) 2007-08-31
TWI335912B (en) 2011-01-11
HUS1800018I1 (hu) 2018-05-28
WO2004096778A1 (de) 2004-11-11
US7196086B2 (en) 2007-03-27
JP2006525249A (ja) 2006-11-09
ECSP056138A (es) 2006-04-19
CN1784390A (zh) 2006-06-07
RU2360912C2 (ru) 2009-07-10
ZA200508710B (en) 2006-12-27
USRE46791E1 (en) 2018-04-17
AU2004233978B2 (en) 2010-02-11
NO333265B3 (no) 2019-06-03
PL1622880T6 (pl) 2018-08-31
ES2284007T7 (es) 2018-06-20
ATE355280T1 (de) 2006-03-15
DK1622880T6 (da) 2018-06-18
FR18C1029I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-08-17
PE20050145A1 (es) 2005-05-22
NL300933I2 (nl) 2018-04-26
CY1106476T1 (el) 2012-01-25
KR100927063B1 (ko) 2009-11-13
CA2524069C (en) 2011-11-08
CY2018019I1 (el) 2018-12-12
HUS1800028I1 (hu) 2018-07-30
PT1622880E (pt) 2007-06-04
US20070191387A1 (en) 2007-08-16
NO20055649D0 (no) 2005-11-30
US8513255B2 (en) 2013-08-20
NO2018022I1 (no) 2018-07-04
NO20055649L (no) 2006-01-31
CY2018019I2 (el) 2018-12-12
AU2004233978A1 (en) 2004-11-11
MY144616A (en) 2011-10-14
EP1622880B1 (de) 2007-02-28
DK1622880T3 (da) 2007-06-25
CL2004000930A1 (es) 2005-03-18
DE502004003052D1 (de) 2007-04-12
EG25273A (en) 2011-12-04
NO333265B1 (no) 2013-04-22
FR18C1029I2 (fr) 2020-07-17
ES2284007T3 (es) 2007-11-01
NZ543317A (en) 2008-05-30
BRPI0410029B8 (pt) 2021-06-15
BRPI0410029B1 (pt) 2019-12-31
EP1622880B3 (de) 2018-05-23
DE10319612A1 (de) 2004-11-18
PL1622880T3 (pl) 2007-08-31
MA27794A1 (fr) 2006-03-01
UA82519C2 (uk) 2008-04-25
AR044078A1 (es) 2005-08-24
CA2524069A1 (en) 2004-11-11
IL171513A (en) 2011-11-30
HK1092463A1 (zh) 2007-02-09
RU2005137276A (ru) 2006-07-27
TW200510343A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
JP4733631B2 (ja) 抗ウイルス性を有する置換されたジヒドロキナゾリン類
US20100179174A1 (en) Substituted azaquinazolines having an antiviral action
JP4734230B2 (ja) 複素環置換ジヒドロキナゾリンおよび抗ウイルス剤としてのその使用
US7960387B2 (en) 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US8314113B2 (en) Substituted dihydroquinazolines II
US7709491B2 (en) Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
HK1092463B (en) Substituted dihydrochinazolines having antiviral properties

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070326

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070507

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081103

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110419

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110422

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4733631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250